
## Sophie E Berends

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3944985/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clinical Pharmacokinetics, 2019, 58, 15-37.	3.5	91
2	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. Gastroenterology, 2019, 157, 997-1006.e6.	1.3	86
3	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scandinavian Journal of Gastroenterology, 2021, 56, 145-154.	1.5	61
4	Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. Therapeutic Drug Monitoring, 2018, 40, 202-211.	2.0	26
5	Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. British Journal of Clinical Pharmacology, 2019, 85, 1544-1551.	2.4	26
6	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. British Journal of Clinical Pharmacology, 2021, 87, 106-118.	2.4	18
7	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scandinavian Journal of Gastroenterology, 2019, 54, 700-706.	1.5	16
8	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. Therapeutic Drug Monitoring, 2020, 42, 289-294.	2.0	13
9	Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. Expert Review of Clinical Pharmacology, 2019, 12, 885-891.	3.1	8
10	Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 543-551.	1.8	8
11	Golimumab for moderate to severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 401-406.	3.0	7
12	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. Journal of Dermatological Treatment, 2022, 33, 2680-2684.	2.2	4
13	Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	2.0	1
14	Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. The Cochrane Library, 2018, , .	2.8	0